94
Participants
Start Date
May 13, 2020
Primary Completion Date
June 10, 2021
Study Completion Date
June 29, 2021
SHR0302
Oral tablets taken once daily (QD)
St George Dermatology and Skin Cancer Centre, Kogarah
Novatrials, Kogarah
Sinclair Dermatology, East Melbourne
Sinclair Dermatology, Melbourne
Skin Health Institute, Carlton
Veracity Clinical Research, Woolloongabba
Skin Search of Rochester, Inc, Rochester
Moore Clinical Research, Brandon
The Skin Wellness Center, Knoxville
Dermatologists of Southwest Ohio, Mason
Dawes Fretzin Clinical Research, Indianapolis
Progressive Clinical Research, San Antonio
Quest Dermatology Research, Northridge
China-Japan Friendship Hospital, Beijing
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Beijing Friendship Hospital, Capital Medical University, Beijing
Beijing Tongren Hospital, Capital Medical University, Beijing
The First Hospital of China Medical University, Shenyang
Shanghai Skin Disease Hospital, Shanghai
Jiangsu Province People's Hospital, Nanjin
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin
The First Affiliated Hospital of Zhejiang University, Hangzhou
SIR RUN RUN Shaw Hospital Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital of Fujian Medical University, Fuzhou
Chongqing Traditional Chinese medicine Hospital, Chongqing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Henan Provincial People's Hospital, Zhengzhou
Guangdong Provincial People's Hospital, Guangzhou
Beijing Friendship Hospital, Capital Medical University, Beijing
Beijing Tongren Hospital, Capital Medical University, Beijing
Peking University People's Hospital, Beijing
The Dermatology Hospital of Nanfang Medical University, Guangzhou
The Dermatology Hospital of Nanfang Medical University, Guangzhou
Reistone Biopharma Company Limited
INDUSTRY